CLL Education
CLL treatment has shifted decisively toward targeted therapies, with BTK inhibitors, BCL-2 inhibitors, and fixed-duration regimens reshaping the treatment landscape. Knowledge Med sessions help community providers navigate these options through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing chronic lymphocytic leukemia face evolving treatment decisions that interactive, independently reviewed education can help address.
- Choosing between continuous BTK inhibition and fixed-duration venetoclax-based regimens
- Interpreting IGHV, TP53, and del(17p) status for risk-adapted treatment
- Managing BTK inhibitor resistance and switching strategies
- Sequencing therapies across multiple lines of treatment
What Sessions Cover
Knowledge Med CLL / SLL sessions use interactive case simulations to address these topics and more.
- First-line therapy selection in CLL: BTK inhibitors vs venetoclax combinations
- Fixed-duration vs continuous therapy: patient selection considerations
- Managing relapsed/refractory CLL after targeted therapy
- Emerging agents: non-covalent BTK inhibitors and bispecific antibodies
Interactive CLL / SLL Sessions
Case Simulations
Work through realistic chronic lymphocytic leukemia patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key CLL / SLL clinical takeaways.
More Hematologic Malignancy Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Diffuse Large B-Cell Lymphoma
DLBCL — Frontline DLBCL: pola-R-CHP and risk-adapted strategies
Multiple Myeloma
Frontline induction: triplet vs quadruplet therapy and transplant decisions
Acute Myeloid Leukemia
AML — Molecular-guided frontline therapy selection in AML
Myelodysplastic Syndromes
MDS — IPSS-M and molecular risk stratification in MDS
Join a CLL / SLL Session
Third-party, non-promotional chronic lymphocytic leukemia education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session